Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Interest Expenses (2022 - 2025)

Coeptis Therapeutics Holdings has reported Interest Expenses over the past 4 years, most recently at -$105145.0 for Q4 2025.

  • Quarterly results put Interest Expenses at -$105145.0 for Q4 2025, down 47.32% from a year ago — trailing twelve months through Dec 2025 was $96744.0 (up 87.57% YoY), and the annual figure for FY2025 was $96744.0, down 60.69%.
  • Interest Expenses for Q4 2025 was -$105145.0 at Coeptis Therapeutics Holdings, down from $62610.0 in the prior quarter.
  • Over the last five years, Interest Expenses for COEPW hit a ceiling of $135671.0 in Q4 2022 and a floor of -$105145.0 in Q4 2025.
  • Median Interest Expenses over the past 4 years was $53372.5 (2022), compared with a mean of $35484.1.
  • Biggest five-year swings in Interest Expenses: plummeted 615.98% in 2024 and later surged 1098.11% in 2025.
  • Coeptis Therapeutics Holdings' Interest Expenses stood at $135671.0 in 2022, then tumbled by 89.8% to $13832.0 in 2023, then plummeted by 615.98% to -$71371.0 in 2024, then tumbled by 47.32% to -$105145.0 in 2025.
  • The last three reported values for Interest Expenses were -$105145.0 (Q4 2025), $62610.0 (Q3 2025), and $67788.0 (Q2 2025) per Business Quant data.